Loading...
Loading...
Loading...
- BeiGene Ltd's BGNE global RATIONALE 305 Phase 3 trial met its primary endpoint of overall survival, with tislelizumab in combination with chemotherapy in patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, regardless of PD-L1 status.
- No new safety signals were identified for tislelizumab.
- BeiGene previously announced superior OS for the combination compared with chemotherapy in the PD-L1 high group at a planned interim analysis, and the trial continued according to pre-specified statistical hierarchy testing.
- Also Read: BeiGene's Tislelizumab Shows Non-Inferiority In Overall Survival, Safety Vs. Standard Treatment In Solid Tumors.
- In the final analysis, tislelizumab, in combination with chemotherapy, demonstrated superior OS compared with chemotherapy in the intent-to-treat (ITT) population.
- Tislelizumab is currently under review by the FDA and the European Medicines Agency (EMA) for advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy.
- The EMA is also reviewing tislelizumab for advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy and in combination with chemotherapy for previously untreated advanced or metastatic NSCLC.
- Price Action: BGNE shares are down 1.37% at $254.95 on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.